Early detection of pancreatic neuroendocrine tumors using blood tests

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of a multi-dimensional fragmentomic assay that analyzes plasma cell-free DNA to detect pancreatic neuroendocrine tumors (pNETs) at an early stage. Given the challenges in diagnosing pNETs early, the study aims to assess the sensitivity and specificity of this non-invasive approach compared to traditional imaging methods. Participants will be adults with a histopathological diagnosis of non-functional pNETs who have not undergone any anti-tumor treatments prior to surgery. Blood samples will be collected to analyze cfDNA fragmentomic profiles, which may provide insights into early tumor detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 and above, regardless of gender;
* Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;
* Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
* No obvious surgical contraindications;
* Able to comply with research plans, follow-up plans, and other protocol requirements;
* Voluntary participation and signed informed consent.

Exclusion Criteria:

* Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;
* Currently diagnosed with other types of tumors or any cancer history;
* Diagnosed with familial syndromes;
* Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
* Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;
* Recipient of blood transfusion within 30 days prior to study blood draw;
* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;
* Poor health condition and not suitable for blood draw;
* Any other disease/condition deemed not suitable for study enrollment by researcher.

Where it's running

• Fudan University shanghai cancer center
  Shanghai, Shanghai Municipality, China Recruiting
• West China Hospital, Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Principal investigator: Xianjun Yu, MD, PhD — Fudan University
• Study coordinator: Xianjun Yu, MD, PhD
• Email: yuxianjun@fudanpci.org
• Phone: 021-64175590-88503

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-guided decision support for managing pancreatic conditions

  This project will test an AI tool that reads contrast-enhanced CT scans to help doctors decide whether people with suspected pancreatic disease need surgery, close monitoring, or routine follow-up.

  Recruiting Changhai Hospital · Shanghai · NCT07439757

• Laparoscopic versus open pancreaticoduodenectomy outcomes

  This trial will test whether laparoscopic (keyhole) pancreaticoduodenectomy leads to fewer complications and faster recovery than open pancreaticoduodenectomy in adults with resectable pancreatic or periampullary tumors.

  Recruiting Minia University · Minya, Minya Governorate · NCT07328607

• Near‑total debulking surgery versus non‑surgical management for metastatic pancreatic neuroendocrine tumours

  This study will test whether removing most of the tumour (near‑total debulking surgery) helps adults with stage 4 non‑functional pancreatic neuroendocrine tumours live longer or feel better compared with not doing debulking.

  Recruiting at 3 sites Uppsala University · Gothenburg and 3 other locations · NCT07273409

• Personalized mRNA vaccine for advanced endocrine tumors

  This study is testing a personalized mRNA vaccine to see if it can help patients with advanced endocrine tumors who haven't had success with standard treatments.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06141369

• Creating personalized 3D models of pancreatic neuroendocrine tumors

  This study is trying to create personalized 3D models of pancreatic neuroendocrine tumors from patients' surgical samples to better understand the disease and test new treatments.

  Recruiting IRCCS San Raffaele · Milan, MI · NCT06121622

• Using chemotherapy after surgery for high-risk pancreatic neuroendocrine tumors

  This study tests if a combination of two chemotherapy drugs can help prevent cancer from coming back in people who have had surgery for high-risk pancreatic neuroendocrine tumors.

  Recruiting at 381 sites Phase 2 SWOG Cancer Research Network · Anchorage, Alaska and 447 other locations · NCT05040360

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.